Genzyme, J&J Manufacturing Troubles Highlight The Importance Of Quality Systems
Executive Summary
Experts say robust quality systems, if taken to heart, can play a key role in preventing and recovering from manufacturing failures like the ones that have struck Genzyme and Johnson & Johnson in recent months.
You may also be interested in...
Sanofi Pursues Genzyme, But For How Long?
Sanofi-Aventis SA's hostile bid for Genzyme Corp. creates difficult choices for the Cambridge, Mass.-based biotech's investors. Do they continue to trust Genzyme's management team, despite its track record of missteps and overly enthusiastic and frequently wrong guidance? Or should they cash out now while there is a clear and certain opportunity?
Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q3 2010
Biopharma financings slumped in the third quarter of 2010 - the $1.69 billion raised in Q3 was about half of Q2's $3.37 billion. Most of the third quarter money came from VC rounds. Two-thirds of the M&A total came from J&J's $2.2 billion purchase of the 82.1% of Crucell that it didn't already own. And following a long stretch in which earlier-stage assets were grabbing the largest deal values, Q3's biopharma alliances proved the contrary - the majority of the biggest moneymakers were for Phase II and higher therapeutics.
Sanofi Pursues Genzyme, But For How Long?
Sanofi-Aventis SA's hostile bid for Genzyme Corp. creates difficult choices for the Cambridge, Mass.-based biotech's investors. Do they continue to trust Genzyme's management team, despite its track record of missteps and overly enthusiastic and frequently wrong guidance? Or should they cash out now while there is a clear and certain opportunity?